An observational study in Prostate Cancer, Breast Cancer and Neuroendocrine Tumors, sponsored by University of California, Davis. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of California, Davis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Prostatic Neoplasms by University of California, Davis — 5 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · University of California, Davis.
Among the 19 studies in Prostatic Neoplasms by University of California, Davis, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 14th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 19 studies in Prostatic Neoplasms by University of California, Davis are open now, in 1 country. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages 18+ · Men only
University of California, Davis · Sites in United States
Ages 18+
University of California, Davis · Sites in United States
Ages 18+ · Men only
University of California, Davis · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 30 across the 15 interventional studies, 102 across the 3 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, Davis is the lead sponsor of 811 studies on the registry; 141 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 43 (64%) have results posted.
3 of the studies in Prostatic Neoplasms by University of California, Davis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06907446University of California, DavisComparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies | 2027-07-01 |
| NCT05160480University of California, DavisA Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Prostatic Neoplasms by University of California, Davis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).
Participants will be recruited by physicians, primary care physicians, radiologists, and research team members who will identify potential participants and notify a research team member to assist with consenting. The research team will also screen potential patients from the oncology clinical schedules. When a potential participant is identified, a member of the research team will contact the referring physician and/or a clinical team member in charge of the patient's care and request permission to contact the patient. If the referring physician/clinical team agrees, a member of the research team will contact the patient.
18F-PSMA (n=3) and 68Ga-PSMA (n=3)
Inclusion criteria:
Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.
68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria for all participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
Diagnostic Test: Total-body PET imaging
Total-body PET imaging at different timepoints
measure radiotracer avidity
measure radiotracer avidity, i.e. standardized uptake value measurements (SUV max and mean) of tumor and normal tissue as a function of time with 18F-PSMA, 18F-FES, 68Ga DOTATATE in a total-body PET scanner among men with suspected prostate cancer metastasis, patients suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors, and patients with recurrent or metastatic breast cancer.
Time frame: One study imaging visit lasting up to 10 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Sep 2027, 38 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 38 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Davis →